.jpg "Miragen Therapeutics Inc (NASDAQ: MGEN)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Miragen Therapeutics Inc (NASDAQ: MGEN), Athersys (NASDAQ: ATHX) and MannKind (NASDAQ: MNKD) with bullish sentiments.
Miragen Therapeutics Inc (NASDAQ: MGEN)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN), with a price target of $19. The company’s shares opened today at $7.49.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.2% and a 45.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Miragen Therapeutics Inc is Strong Buy and the average price target is $16.42, representing an 119.2% upside.
In a report issued on June 5, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.
See today’s analyst top recommended stocks >>
Athersys (NASDAQ: ATHX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Athersys (NASDAQ: ATHX) today and set a price target of $6. The company’s shares opened today at $3.05, close to its 52-week high of $3.09.
McCarthy noted:
“Athersys announced an expanded agreement with Helios KK (6927JP – NR) that includes additional indications and will bring in an additional $20M in capital to Athersys. In association with this deal, Dr. Hardy Kagimoto, CEO of Helios has been nominated for election (June 18, 2018) to the Athersys board of directors.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 13.8% and a 44.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $6.
MannKind (NASDAQ: MNKD)
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on MannKind (NASDAQ: MNKD), with a price target of $5. The company’s shares opened today at $2.03, close to its 52-week low of $1.09.
Livnat wrote:
“We believe the existing treprostinil formulations suffer from clear deficiencies with very complicated and onerous drug delivery and/or dosing-limitations which likely limit efficacy. Due in large part to these limitations, in our view, prostacyclins are only used by about 20% of the 30,000 diagnosed U.S. PAH patients despite 80% being eligible. MannKind will pursue an expedited 505(b)2 bioequivalence pathway now, and could start a pivotal Tyvaso switching study in PAH patients in 2H18. We will wait to see some data first, but theoretically, TreT could be filed by end-2019 and get some credit from the market soon. If successful, we are confident that Technosphere treprostinil, or “TreT,” could represent a material innovation in the PAH prostacyclin space, even with only switching and bioequivalence data.”
According to TipRanks.com, Livnat is a 1-star analyst with an average return of -3.4% and a 50.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
MannKind has an analyst consensus of Moderate Buy, with a price target consensus of $5.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MNKD:
